Form 4: Neurocrine Biosciences Director Reports Stock Transactions

Director Johanna Mercier reports acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Summary

• Johanna Mercier, a director of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On May 22, 2025, Mercier disposed of 1,435 shares of common stock.
• Also on May 22, 2025, Mercier disposed of 1,435 Restricted Stock Units.
• On May 21, 2025, Mercier acquired 3,318 Restricted Stock Units that will vest in full on May 21, 2026.
• Following these transactions, Mercier directly owns 3,535 shares of Neurocrine Biosciences common stock and no Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information about insider trading activity.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors seeking to understand management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may be interested in these transactions as they provide insight into a director's view of the company's stock value.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Neurocrine Biosciences, Director, NBIX, Mercier